CA Patent

CA2580857A1 — Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors

Assigned to Xenon Pharmaceuticals Inc · Expires 2006-09-28 · 20y expired

What this patent protects

Methods of treating an SCD-mediated disease or condition in a mammal, preferebly a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R2, R3, R5 , R5a, R6, R6a, R7, R7a, R8 and R8a …

USPTO Abstract

Methods of treating an SCD-mediated disease or condition in a mammal, preferebly a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R2, R3, R5 , R5a, R6, R6a, R7, R7a, R8 and R8a are difined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA2580857A1
Jurisdiction
CA
Classification
Expires
2006-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Xenon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.